<DOC>
	<DOCNO>NCT01422369</DOCNO>
	<brief_summary>This Phase 4 , single center , open label , fixed-sequence , multiple dose , 2-way drug-drug interaction study .</brief_summary>
	<brief_title>Drug-Drug Interaction Darunavir/Ritonavir Pitavastatin</brief_title>
	<detailed_description>This Phase 4 , single center , open label , fixed-sequence , 2-way drug-drug interaction study . Each subject qualify entry study 30 day admission clinical unit . Subjects check clinical unit Day -1 baseline assessment . There 1 treatment period , subject receive daily dose pitavastatin 4 mg Days 1 5 Days 12 16 daily dose darunavir/ritonavir 800 mg/100 mg Days 6 16 . On Days 1 4 , 6 10 , 12 15 , study drug administer 30 minute standard breakfast . On Days 5 , 11 , 16 , subject fast least 8 hour receive study drug remain fasted 4 hour dose .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Healthy adult male female volunteer age 18 45 year , inclusive . Subject body mass index 18 30 kg/m2 , inclusive . Subject normal hematology , serum chemistry , urinalysis test result Subject able willing abstain alcohol , grapefruit , caffeine caffeine containing product , St John 's wort , herbal supplement 4 day Day 1 completion study Subject nonsmoker quit smoke least 6 month first dose study drug study completion . Subject surgery gastrointestinal tract likely affect drug absorption , distribution , metabolism , excretion . Subject previous allergy intolerance treatment pitavastatin , darunavir , ritonavir , sulfonamide , drug class . Subject history drug alcohol abuse . Subject clinically significant illness within 4 week first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>